Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024

06 Mar 2024
www.biospace.com
AACRADC
AU ZH, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will be presenting one abstract and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. Presentation details are summarized below: Abstract Title: Novel dual TOP1i ADC inducing superior tumor growth inhibition at low-drug load vs. trastuzumab deruxtecan Presenter: Philipp Spycher, Ph.D. Session Category: Immunology Session Title: Antibody-Drug Conjugates Date and Time: Monday April 8, 2024, 1:30 – 5:00 PM PT Poster Board Number: 3, Section 2 Abstract Title: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo Presenter: Isabella Attinger-Toller, Ph.D. Session Title: Late-Breaking Research: Immunology 2 Date and Time: Monday, April 8, 2024, 9:00 AM – 12:30 PM PT Poster Board Number: 12, Section 52 About Araris Biotech AG Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for unparalleled efficacy and tolerability. With a strong commitment to transforming the landscape of ADCs, Araris leverages its proprietary, ready-to-use linker-payload platforms and site-specific conjugation techniques to create a new frontier in targeted therapeutics. The company’s innovative approach ensures that ADCs are generated to be highly efficacious and tolerable as exemplified in experiments using its topoisomerase- and auristatin- based linker-payloads, potentially providing patients with groundbreaking treatment options for diseases of high unmet medical needs. For more information, please visit or follow Araris on X and LinkedIn. Corporate Contact: Dragan Grabulovski, Ph.D. Acting Chief Executive Officer info@ararisbiotech.com Media Contact: Veronica Eames LifeSci Communications, LLC veames@lifescicomms.com 646-970-4682
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.